PT97277B - Processo para a preparacao de formulacoes farmaceuticas, contendo, por exemplo, ciclosporina a e factor de veneno de cobracapelo, uteis para a inibicao da rejeicao de aloenxerto e de xenoenxerto concordante - Google Patents
Processo para a preparacao de formulacoes farmaceuticas, contendo, por exemplo, ciclosporina a e factor de veneno de cobracapelo, uteis para a inibicao da rejeicao de aloenxerto e de xenoenxerto concordante Download PDFInfo
- Publication number
- PT97277B PT97277B PT97277A PT9727791A PT97277B PT 97277 B PT97277 B PT 97277B PT 97277 A PT97277 A PT 97277A PT 9727791 A PT9727791 A PT 9727791A PT 97277 B PT97277 B PT 97277B
- Authority
- PT
- Portugal
- Prior art keywords
- cyclosporin
- venom
- graft
- immunosuppressant
- complement inhibitor
- Prior art date
Links
- 108010036949 Cyclosporine Proteins 0.000 title claims abstract description 56
- 229930105110 Cyclosporin A Natural products 0.000 title claims abstract description 55
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 55
- 229960001265 ciclosporin Drugs 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 12
- 231100000614 poison Toxicity 0.000 title description 6
- 239000002574 poison Substances 0.000 title description 6
- 230000005764 inhibitory process Effects 0.000 title description 3
- 238000006243 chemical reaction Methods 0.000 title description 2
- 230000004083 survival effect Effects 0.000 claims abstract description 39
- 230000000694 effects Effects 0.000 claims abstract description 32
- 239000004074 complement inhibitor Substances 0.000 claims abstract description 22
- 229930182912 cyclosporin Natural products 0.000 claims abstract description 21
- 229940124073 Complement inhibitor Drugs 0.000 claims abstract description 20
- 210000002925 A-like Anatomy 0.000 claims abstract description 12
- 239000003998 snake venom Substances 0.000 claims description 22
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 19
- 230000001861 immunosuppressant effect Effects 0.000 claims description 19
- 239000003018 immunosuppressive agent Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 101710181904 Venom factor Proteins 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 7
- 230000024203 complement activation Effects 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims 3
- 230000036039 immunity Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 210000002268 wool Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 101710172562 Cobra venom factor Proteins 0.000 abstract 1
- 231100000611 venom Toxicity 0.000 description 38
- 239000002435 venom Substances 0.000 description 36
- 210000001048 venom Anatomy 0.000 description 36
- 241000894007 species Species 0.000 description 17
- 238000002054 transplantation Methods 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 11
- 241000700159 Rattus Species 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 241000270295 Serpentes Species 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000002642 cobra venom Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 229920002567 Chondroitin Polymers 0.000 description 3
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000003712 Complement factor B Human genes 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000050019 Membrane Cofactor Human genes 0.000 description 2
- 101710146216 Membrane cofactor protein Proteins 0.000 description 2
- 241000272140 Naja kaouthia Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JTOKYIBTLUQVQV-QRVTZXGZSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-[(1r)-1-hydroxyethyl]-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontan Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H]([C@@H](C)O)NC1=O JTOKYIBTLUQVQV-QRVTZXGZSA-N 0.000 description 1
- GNGBSKIQPUCELM-YBAOVNABSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-[(e,2r)-2-methylhex-4-enyl]-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29, Chemical compound CC[C@@H]1NC(=O)[C@H](C[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O GNGBSKIQPUCELM-YBAOVNABSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000757814 Canis lupus x Canis lupus familiaris Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- JTOKYIBTLUQVQV-UHFFFAOYSA-N Cyclosporin C Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O JTOKYIBTLUQVQV-UHFFFAOYSA-N 0.000 description 1
- GNGBSKIQPUCELM-UHFFFAOYSA-N Cyclosporin F Natural products CCC1NC(=O)C(CC(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O GNGBSKIQPUCELM-UHFFFAOYSA-N 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000272060 Elapidae Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010048748 Graft loss Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000271897 Viperidae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229940052810 complex b Drugs 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 108010019248 cyclosporin C Proteins 0.000 description 1
- 108010019252 cyclosporin F Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960003569 hematoporphyrin Drugs 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909007971A GB9007971D0 (en) | 1990-04-09 | 1990-04-09 | Pharmaceutical formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PT97277A PT97277A (pt) | 1992-01-31 |
| PT97277B true PT97277B (pt) | 1998-08-31 |
Family
ID=10674123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97277A PT97277B (pt) | 1990-04-09 | 1991-04-08 | Processo para a preparacao de formulacoes farmaceuticas, contendo, por exemplo, ciclosporina a e factor de veneno de cobracapelo, uteis para a inibicao da rejeicao de aloenxerto e de xenoenxerto concordante |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0527762B1 (enExample) |
| JP (1) | JP3518547B2 (enExample) |
| CN (1) | CN1040178C (enExample) |
| AT (1) | ATE141167T1 (enExample) |
| AU (1) | AU7555591A (enExample) |
| CZ (1) | CZ283119B6 (enExample) |
| DE (1) | DE69121401T2 (enExample) |
| DK (1) | DK0527762T3 (enExample) |
| ES (1) | ES2090325T3 (enExample) |
| GB (1) | GB9007971D0 (enExample) |
| GR (1) | GR3021642T3 (enExample) |
| HK (1) | HK48597A (enExample) |
| IE (1) | IE911153A1 (enExample) |
| IL (1) | IL97788A (enExample) |
| IN (1) | IN173149B (enExample) |
| MY (1) | MY106158A (enExample) |
| NZ (1) | NZ237739A (enExample) |
| PT (1) | PT97277B (enExample) |
| SG (1) | SG47465A1 (enExample) |
| SK (1) | SK279949B6 (enExample) |
| WO (1) | WO1991015221A1 (enExample) |
| ZA (1) | ZA912467B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE297217T1 (de) | 1999-10-27 | 2005-06-15 | Alexandra Lucas | Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung |
| US7419670B2 (en) | 2000-09-29 | 2008-09-02 | Viron Therapeutics, Inc. | Method of treating arthritis with SERP-1 and an immunosuppressant |
| EP2338511A3 (en) * | 2004-05-14 | 2012-07-25 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| US7285530B2 (en) | 2004-10-21 | 2007-10-23 | Viron Therapeutics, Inc. | Use of SERP-1 as an antiplatelet agent |
| LT3028716T (lt) | 2006-10-10 | 2020-12-10 | Regenesance B.V. | Komplemento slopinimas nervų regeneracijos pagerinimui |
| JP6223659B2 (ja) | 2008-11-10 | 2017-11-01 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体関連障害を処置するための方法および組成物 |
| AU2014306002B2 (en) | 2013-08-07 | 2017-05-25 | Alexion Pharmaceuticals, Inc. | Atypical hemolytic uremic syndrome (aHUS) biomarker proteins |
| WO2026064591A1 (en) * | 2024-09-20 | 2026-03-26 | Antinous Technology Company Limited | Methods and compositions for preventing herpes virus reactivation in organ xenograft |
-
1990
- 1990-04-09 GB GB909007971A patent/GB9007971D0/en active Pending
-
1991
- 1991-04-02 MY MYPI91000550A patent/MY106158A/en unknown
- 1991-04-03 IN IN265MA1991 patent/IN173149B/en unknown
- 1991-04-03 ZA ZA912467A patent/ZA912467B/xx unknown
- 1991-04-04 EP EP91907303A patent/EP0527762B1/en not_active Expired - Lifetime
- 1991-04-04 AU AU75555/91A patent/AU7555591A/en not_active Abandoned
- 1991-04-04 DE DE69121401T patent/DE69121401T2/de not_active Expired - Fee Related
- 1991-04-04 ES ES91907303T patent/ES2090325T3/es not_active Expired - Lifetime
- 1991-04-04 DK DK91907303.1T patent/DK0527762T3/da active
- 1991-04-04 JP JP50651691A patent/JP3518547B2/ja not_active Expired - Fee Related
- 1991-04-04 SG SG1996001900A patent/SG47465A1/en unknown
- 1991-04-04 AT AT91907303T patent/ATE141167T1/de not_active IP Right Cessation
- 1991-04-04 WO PCT/GB1991/000522 patent/WO1991015221A1/en not_active Ceased
- 1991-04-08 IL IL97788A patent/IL97788A/en not_active IP Right Cessation
- 1991-04-08 NZ NZ237739A patent/NZ237739A/xx unknown
- 1991-04-08 PT PT97277A patent/PT97277B/pt not_active IP Right Cessation
- 1991-04-08 IE IE115391A patent/IE911153A1/en not_active IP Right Cessation
- 1991-04-09 CN CN91102859A patent/CN1040178C/zh not_active Expired - Fee Related
- 1991-04-09 CZ CS91988A patent/CZ283119B6/cs not_active IP Right Cessation
- 1991-04-09 SK SK988-91A patent/SK279949B6/sk unknown
-
1996
- 1996-11-14 GR GR960403013T patent/GR3021642T3/el unknown
-
1997
- 1997-04-17 HK HK48597A patent/HK48597A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK48597A (en) | 1997-04-25 |
| IL97788A (en) | 1998-02-08 |
| JPH05507266A (ja) | 1993-10-21 |
| IE911153A1 (en) | 1991-10-09 |
| DK0527762T3 (da) | 1996-09-02 |
| CN1056240A (zh) | 1991-11-20 |
| GR3021642T3 (en) | 1997-02-28 |
| SG47465A1 (en) | 1998-04-17 |
| IN173149B (enExample) | 1994-02-19 |
| GB9007971D0 (en) | 1990-06-06 |
| EP0527762A1 (en) | 1993-02-24 |
| AU7555591A (en) | 1991-10-30 |
| MY106158A (en) | 1995-03-31 |
| ZA912467B (en) | 1992-12-30 |
| CN1040178C (zh) | 1998-10-14 |
| EP0527762B1 (en) | 1996-08-14 |
| IL97788A0 (en) | 1992-06-21 |
| WO1991015221A1 (en) | 1991-10-17 |
| ATE141167T1 (de) | 1996-08-15 |
| JP3518547B2 (ja) | 2004-04-12 |
| CZ283119B6 (cs) | 1998-01-14 |
| NZ237739A (en) | 1993-09-27 |
| DE69121401T2 (de) | 1996-12-12 |
| ES2090325T3 (es) | 1996-10-16 |
| SK279949B6 (sk) | 1999-06-11 |
| CS9100988A2 (en) | 1991-12-17 |
| PT97277A (pt) | 1992-01-31 |
| DE69121401D1 (de) | 1996-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marsolais et al. | Neutrophils and macrophages accumulate sequentially following Achilles tendon injury | |
| EP0343241B1 (en) | A method of inhibiting platelet dependent arterial thrombosis | |
| EP0631784B1 (en) | Sulphated polysaccharides having anti-inflammatory activity | |
| Coffey et al. | Heparin inhibits mesangial cell proliferation in habu-venom-induced glomerular injury | |
| WO1995029694A1 (en) | Collagen hydrolysis accelerator | |
| RU2014837C1 (ru) | Средство для лечения панкреатита и предупреждения отторжения трансплантата поджелудочной железы и способ предупреждения отторжения трансплантата поджелудочной железы | |
| SK7062003A3 (en) | Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament | |
| US7897561B2 (en) | Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury | |
| EP0527762B1 (en) | Inhibition of allograft and concordant xenograft rejection | |
| PT99057B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo uma mistura sinergica de glicoproteina cd4 da superficie das ceelulas ou de um seu analogo com um agente polianionico anti-hiv, nomeadamente um polissacarido sulfatado | |
| Mann Jr et al. | Antithrombin III: Protection against death after injection of thromboplastin | |
| Chucrallah et al. | Lovastatin/gemfibrozil myopathy: a clinical, histochemical, and ultrastructural study | |
| US20010018051A1 (en) | Inhibition of allograft and concordant xenograft rejection | |
| Thompson et al. | Studies on the humoral control of gastric secretion in dogs with autogenous and homotransplanted antral and fundic pouches | |
| WO1998039016A1 (en) | Immune tolerance inducers | |
| Lucas et al. | Renal allotransplantation in man: II. Transplantation in cystinosis, a metabolic disease | |
| Enomoto et al. | Therapeutic Trials in Muscular Dystrophy: III. Studies of Microbial Proteinase Inhibitors in Murine Dystrophy | |
| ROSENBERG et al. | INHIBITION OF DESOXYCORTICOSTERONEINDUCED PATHOLOGIC CHANGES BY ADRENOCORTICOTROPIC HORMONE AND CORTISONE | |
| CA2171509A1 (en) | Method of treating acute myocardial infarction with hirudin and acetylsalicylic acid in patients not undergoing thrombolytic treatment | |
| Iomhair et al. | Effect of aspirin-dipyridamole and heparin and their combination on venous thrombosis in hypercoagulable or thrombotic animals | |
| CN1819839B (zh) | 免疫调节化合物和相关方法 | |
| Reece et al. | Early results of cardiac transplantation at the Texas Heart Institute. | |
| JPH11199508A (ja) | 臓器不全治療剤 | |
| RU2024139947A (ru) | Фитусиран для лечения гемофилии a и b у пациентов детского возраста | |
| Levi et al. | Pharmacological Strategies to Decrease Excessive Blood Loss in Cardiac Surgery: Meta‐analysis of Clinically Relevant Endpoints |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB1A | Laying open of patent application |
Effective date: 19910911 |
|
| FG3A | Patent granted, date of granting |
Effective date: 19980504 |
|
| MM4A | Annulment/lapse due to non-payment of fees, searched and examined patent |
Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20071105 |